L-γ-Methyleneglutamine Compounds for Selective Glutamine-Pathway Targeting
Solution Overview
Problem
Existing glutamine metabolism inhibitors for cancer treatment exhibit non-selectivity, leading to significant gastrointestinal toxicity and myelosuppression, while new agents targeting specific nodes of glutamine metabolism are sought to overcome these issues.
Innovation Solution
Development of an efficient synthetic route to produce L-γ-methyleneglutamine and its amide derivatives, which are evaluated for their anticancer activity on breast cancer cell lines, utilizing a novel amide coupling protocol and tert-butyl group protection for carboxylic acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naturally occurring glutamine analogues (azaserine, acivicin, DON) are used to inhibit glutamine metabolism in cancer, then tumor growth suppression is achieved, but gastrointestinal toxicity and myelosuppression occur due to non-selectivity
Solution Approach 1:
The patent applies local quality by designing L-γ-methyleneglutamine and its amide derivatives with specific molecular structures that target glutamine metabolism pathways selectively in cancer cells. The compounds exhibit preferential uptake and metabolic disruption in glutamine-dependent cancer cells while sparing normal tissues, thereby achieving local therapeutic action at the cellular level rather than systemic toxicity
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of glutamine analogues - specifically introducing the L-γ-methylene group and various amide substitutions - to alter the biological activity profile. These structural modifications enhance selectivity for cancer cell targets while reducing off-target effects that cause gastrointestinal toxicity and myelosuppression
2Reliability
If existing glutamine metabolism inhibitors are administered, then anticancer activity is achieved, but selectivity is poor leading to systemic side effects
Solution Approach 1:
The compounds are designed with specific structural features (L-γ-methylene group and amide derivatives) that enable selective interaction with cancer cell metabolism. The molecular structure allows preferential accumulation in glutamine-dependent cancer cells through activated amino acid transporters, achieving local therapeutic action while minimizing systemic exposure and side effects
Data Source
AI summary
Disclosed are substantially pure L-y-methyleneglutamine, L-y-methyleneglutamic acid, and/or amide derivatives, and methods of use thereof. In particular, the presently disclosed subject matter relates to L-y-methyleneglutamine, L-y-methyleneglutamic acid, and/or amide derivatives thereof, and methods of treating cancer. The method comprises administering one or more substantially pure L-y-methyleneglutamine, L-y-methyleneglutamic acid, and/or amide derivatives to a subject in need thereof.